Oral Sessions (Day1, Day2, Day3)
Poster Presentations (Day1, Day2, Day3)
Oral Sessions
- Day 2, June 23（Thu.） 9:00-9:20 Room A (Main Hall)
-
2A-O1-0900 PDF
Development for Evaluation of the Kinetics of Drugs with New Modality by Imaging Mass Spectrometry
In order to accelerate drug discovery, it is necessary to speed up and streamline the drug development process, and under government support, development of pharmacokinetics technology is being promoted.
While mass spectrometry of blood, urine, and feces is widely used for pharmacokinetic measurements, autoradiography and PET have been used for imaging analysis of the whole body from the viewpoint of sensitivity and other factors. Therefore, we have launched a project to construct a next-generation kinetic evaluation platform by expanding the modality of imaging mass spectrometry (IMS) of large size samples from conventional low-molecular weight mass spectrometry to the mid-molecular weight mass spectrometry.
To this end, we will develop a novel ambient ion source to optimize the mid-molecular weight drug imaging and practical analysis of pharmacokinetics. A temperature-controllable device will be developed for pharmacokinetics with noise reduction and postmortem change control. AI for internal standard calibration will be also developed based on nonlinear statistical processing to quantitatively evaluate big IMS data.
Our research and development have been adopted by the AMED project and we would like to give an overview of the project and its challenging efforts in this presentation.